Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     
  • OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD

    2,406.70
    +8.70 (+0.36%)
     
  • Bitcoin AUD

    99,182.59
    +3,878.31 (+4.07%)
     
  • CMC Crypto 200

    1,367.15
    +54.52 (+4.15%)
     
  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     
  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Berkeley Lights Reports First Quarter 2021 Financial Results

Q1 2021 revenue increased 35% year over year

EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended March 31, 2021.

Recent Highlights

  • Total revenue of $18.6 million for the first quarter of 2021, representing 35% growth year over year

  • Grew the installed base to 85 platforms during the first quarter of 2021, with eight new direct placements and two existing platforms added upon the successful completion of a joint development and partnership program

  • Announced the launch of Opto Assure, the first of a series of assays that will provide yield and product quality data at an earlier stage in cell development

ADVERTISEMENT
  • Appointed Greg Lucier as Chairperson and John Chiminski as an Independent Director to its Board of Directors

“We started the year with strong platform placements, continued to expand opportunities in our core business and grew our total addressable market,” said Berkeley Lights Chief Executive Officer Eric Hobbs, Ph.D. “As we look ahead in 2021, I continue to be excited about the opportunities in front of us and I am confident that we are well positioned to execute our strategy to transform the market for cell-based products this year and beyond.”

First Quarter 2021 Financial Results

Three Months Ended March 31,

(in thousands, except per share data)

2021

2020

(unaudited)

(unaudited)

Revenue

$

18,628

$

13,778

Gross profit

12,451

9,979

Gross margin %

67

%

72

%

Operating expenses

27,600

18,207

Loss from operations

(15,149

)

(8,228

)

Net loss and net comprehensive loss

(15,435

)

(8,425

)

Net loss attributable to common stockholders per share, basic and diluted

(0.24

)

(3.02

)

Total stock-based compensation

4,494

1,179

2021 Outlook

Berkeley Lights continues to expect full year 2021 revenue to be in the range of $90 million to $100 million, representing 40% to 56% growth over the full year of 2020.

Webcast and Conference Call Information

Berkeley Lights will host a conference call to discuss the first quarter 2021 financial results before market open on Tuesday, May 11, 2021 at 5:30 a.m. Pacific Time/8:30 a.m. Eastern Time. A webcast of the conference call can be accessed at http://investors.berkeleylights.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Berkeley Lights

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Press Contact
berkeleylights@bulleitgroup.com

Investor Contact
ir@berkeleylights.com


Berkeley Lights, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except share and per share data)

Three months ended March 31,

2021

2020

Revenue:

Product revenue

$

13,533

$

10,683

Service revenue

5,095

3,095

Total revenue

18,628

13,778

Cost of sales:

Product cost of sales

3,703

2,620

Service cost of sales

2,474

1,179

Total cost of sales

6,177

3,799

Gross profit

12,451

9,979

Operating expenses:

Research and development

13,027

10,976

General and administrative

8,967

3,997

Sales and marketing

5,606

3,234

Total operating expenses

27,600

18,207

Loss from operations

(15,149

)

(8,228

)

Other income (expense):

Interest expense

(354

)

(357

)

Interest income

66

151

Other income (expense), net

19

25

Loss before income taxes

(15,418

)

(8,409

)

Provision for income taxes

17

16

Net loss and net comprehensive loss

$

(15,435

)

$

(8,425

)

Net loss attributable to common stockholders per share, basic and diluted

$

(0.24

)

$

(3.02

)

Weighted-average shares used in calculating net loss per share, basic and diluted

65,259,398

3,047,967


Berkeley Lights, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)

Assets

March 31,
2021

December 31,
2020

(unaudited)

Current assets:

Cash and cash equivalents

$

230,165

$

233,408

Trade accounts receivable

16,432

12,939

Inventory

10,941

11,047

Prepaid expenses and other current assets

8,240

8,175

Total current assets

265,778

265,569

Restricted cash

270

270

Property and equipment, net

17,152

14,544

Operating lease right-of-use assets

16,223

16,718

Other assets

3,528

2,557

Total assets

$

302,951

$

299,658

Liabilities and Stockholders’ Equity

Current liabilities:

Trade accounts payable

$

6,934

$

3,491

Accrued expenses and other current liabilities

8,153

8,401

Current portion of notes payable

16,592

11,594

Deferred revenue

7,929

5,482

Total current liabilities

39,608

28,968

Notes payable, net of current portion

3,320

8,301

Deferred revenue, net of current portion

2,301

1,709

Lease liability, long-term

15,356

15,899

Total liabilities

60,585

54,877

Stockholders’ equity:

Convertible preferred stock

Common stock

4

3

Additional paid-in capital

449,681

436,662

Accumulated deficit

(207,319

)

(191,884

)

Total stockholders’ equity

242,366

244,781

Total liabilities and stockholders’ equity

$

302,951

$

299,658